US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Agreement with Novartis on OX17 for GERD terminated

    Uppsala, Sweden – February 25, 2013 - Orexo AB today announced that Novartis AG has sent a notice of termination of the license agreement dated August 27, 2009. The OX17 program was aimed for the treatment of gastroesophageal reflux disease (GERD) and is still in early clinical phase. Under the license agreement, Novartis was responsible for all development, production and marketing of future products. The OX17 program has not developed according to plans and given the strategic direction which Orexo has taken, the program will be discontinued. The termination of OX17 will have no

    Orexo AB (publ.) – Year-end Report January-December 2009

    Uppsala, February 17, 2010 Orexo AB (publ) – Year-end Report January–December 2009 Key events during the year • Net revenues totaled MSEK 236.1 (233.3). • The loss after tax was MSEK 98.1 (loss: 103.1). • The loss per share amounted to a loss of SEK 4.32 (loss: 4.77). • Cash and cash equivalents at year-end totaled MSEK 87.4 (188.2). • Abstral was launched in UK, Germany, France, Spain and Greece. • In March, the FDA approved Orexo’s product Edluar for the short-term treatment of insomnia. The approval resulted in Orexo receiving a milestone payment of MUSD 5 from Meda. • In August, Orexo

    Orexo AB (publ) – Interim report January-September 2009

    Uppsala, November 10, 2009 Orexo AB (publ) – Interim report January-September 2009 Key events during the period • Net revenues amounted to MSEK 208.2 (141.2). • The loss after tax was MSEK 40.1 (loss: 88,6). • The loss per share was SEK 1.78 (loss: 4.10). • Cash and cash equivalents at the end of the quarter totaled MSEK 107.1 (195.7). • In March, the US Food and Drug Administration (FDA) approved Orexo’s Edluar product for the treatment of short-term insomnia. The approval meant that Orexo received a milestone payment of MUSD 5 from Meda. • In February, Orexo signed an exclusive

    Orexo signs exclusive worldwide license agreement for a novel formulation

    Uppsala, Sweden, 28 August, 2009 - Orexo (STO: ORX) announces it has signed an exclusive worldwide licensing agreement with a Novartis affiliate to develop and commercialise a novel product related to Orexo’s OX17 program. Under the terms of the agreement, Novartis will fund all future development of the new product and will receive an exclusive license to all related intellectual property. Orexo will receive milestone payments upon major development achievements, and will be eligible for further milestone payments upon the attainment of certain sales targets. In addition, Orexo will

    Orexo signs an exclusive development agreement for its OX17 program

    Orexo has signed an exclusive development agreement with a large healthcare company, providing for joint development within Orexo’s OX17 program for gastroesophageal reflux disease (GERD), and will be discontinuing all other licensing discussions for Ox17.During this development work, Orexo will continue negotiations to enter into an appropriate global exclusive license agreement including the whole of Orexo’s Ox17 program and related intellectual property. This license agreement is anticipated during 2009. The financial terms were not disclosed.Torbjörn Bjerke, President and CEO of

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media